Call for Greater Adoption of Recommended Standards during Cancer Drug Development to Improve Cancer Care with CKD
Author:
Affiliation:
1. Early Cardiovascular Renal and Metabolism Research and Development, AstraZeneca, Gaithersburg, Maryland
2. Department of Medicine, Duke University, Durham, North Carolina
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology
Reference9 articles.
1. Chronic kidney disease and cancer: inter-relationships and mechanisms;Hu;Front Cell Dev Biol.,2022
2. Inclusion of participants with CKD and other kidney-related considerations during clinical drug development: landscape analysis of anticancer agents approved from 2015 to 2019;Butrovich;Clin J Am Soc Nephrol.,2023
3. Evaluating patients with impaired renal function during drug development: highlights from the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting;Sahre;Clin Pharmacol Ther.,2021
4. Are we ready to include organ-impaired patients in oncology trials? A clinical pharmacology perspective on recent recommendations;Masters;J Clin Pharmacol.,2018
5. Impact of broadening trial eligibility criteria for patients with advanced non-small cell lung cancer: real-world analysis of select ASCO-Friends recommendations;Harvey;Clin Cancer Res.,2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3